JERSEY CITY, N.J., May 23, 2018 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovativetherapies for difficult-to-treat and often life-threatening infections, today announced that Marco Taglietti, M.D., President and Chief Executive Officer of SCYNEXIS, will participate in a panel at the 2018 BIO International
About SCYNEXISSCYNEXIS, Inc. (NASDAQ:SCYX) is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by developing innovative anti-infective therapies. The SCYNEXIS team has extensive experience in the life sciences industry, discovering and developing more than 30 innovative medicines over a broad range of therapeutic areas. The Company's lead product candidate, SCY-078, is a novel IV/oral antifungal agent in Phase 2 clinical and pre-clinical development for the treatment of multiple serious and life-threatening invasive fungal infections caused by Candida and Aspergillus species. For more information, visit www.scynexis.com.
Media RelationsGeorge E. MacDougallMacDougall Biomedical CommunicationsTel: firstname.lastname@example.org
Investor RelationsSusan KimArgot PartnersTel: email@example.com
View original content:http://www.prnewswire.com/news-releases/scynexis-to-participate-in-a-panel-at-the-2018-bio-international-convention-300652176.html
SOURCE SCYNEXIS, Inc.
Subscribe to our Free Newsletters!
Oxidative stress is a form of injury to body tissues due to increase in free radicals. If the ...
Graviola's health benefits range from curing headaches to fighting cancer. Read on to know more ...
Gene therapy is a specialized procedure where genetic material is introduced into the cells of a ...View All